Delivery Order SPE2DB24D8001-SPE2DB25FKYTN

Award Date 10/24/24
Potential Completion Date 10/25/24
Potential Value $1.3K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Anoka, MN, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) awarded a Firm Fixed Price delivery order contract to Dakota Drug, Inc., a self-certified small disadvantaged business, for the purchase of WEGOVY 0.25 MG/0.5 ML PEN 0.5ML pharmaceutical products. The contract has a total ceiling value of $15,933.58 and a period of performance through November 18, 2024. Dakota Drug, Inc. holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical division under the ECAT Generation V...
This firm fixed-price delivery order contract was awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Dakota Drug, Inc., a self-certified small disadvantaged business operating as a for-profit Subchapter S corporation. The $3,563.88 award is for the supply of WEGOVY 2.4 MG/0.75 ML PEN 0.75ML, a pharmaceutical product. This contract supports the DLA Troop Support Medical's mission of providing comprehensive medical supply chain operations for the U.S. Armed Forces. The contract...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business, for the delivery of WEGOVY 2.4 MG/0.75 ML PEN 0.75ML pharmaceutical products. The contract, identified as SPE2DB24D8001|SPE2DB25FKYZP, is a Firm Fixed Price Delivery Order with a ceiling value of $3,486.24 and a performance period through January 6, 2025. Dakota Drug, Inc. holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award, valued at $5,256.21, was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business operating as a for-profit subchapter S corporation. The contract is a firm fixed-price delivery order for the pharmaceutical product "WEGOVY 1 MG/0.5 ML PEN 0.5ML". This award is part of a larger Indefinite Delivery Contract (IDC) between Dakota Drug, Inc. and the DLA Troop Support Medical's ECAT Generation V Program,...
This is a firm fixed-price delivery order awarded by the U.S. Department of Defense's Medical Supply Chain organization (also known as the Defense Logistics Agency (DLA) Troop Support Medical) to Dakota Drug, Inc., a self-certified small disadvantaged business operating as a for-profit subchapter S corporation. The $4,897.22 contract is for the delivery of WEGOVY 0.5 MG/0.5 ML PEN 0.5ML, a prescription medication, with a performance period ending on April 25, 2024. The contract was awarded on...
The Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract to Dakota Drug, Inc., a self-certified small disadvantaged business, for the procurement of 0.25 mg/0.5 mL pens of the pharmaceutical product WEGOVY. The contract has a ceiling value of $3,634.12 and a performance period ending on January 3, 2025. This contract award is part of Dakota Drug, Inc.'s existing Indefinite Delivery Contract (IDC) SPE2DB24D8001, valued at $999,999,999.00, which allows the company to...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical division to Dakota Drug, Inc., a self-certified small disadvantaged business. The $1,938.23 firm fixed-price contract is for the delivery of WEGOVY 2.4 MG/0.75 ML PEN 0.75ML, a prescription pharmaceutical product. The contract has a performance period through February 12, 2024. Dakota Drug, Inc. also holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award, valued at $2,661.64, was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract is for the delivery of the pharmaceutical product "WEGOVY 0.5 MG/0.5 ML PEN 0.5ML" and has a performance period through November 8, 2024. Dakota Drug, Inc. is a key supplier of pharmaceutical products, medical supplies, and healthcare equipment to the U.S. Department of Defense. This award is a delivery...
This federal contract award, valued at $3,071.33, was issued by the Defense Logistics Agency (DLA) to the prime contractor Dakota Drug, Inc., a self-certified small disadvantaged business. The contract is a delivery order for the pharmaceutical product WEGOVY 2.4 MG/0.75 ML PEN 0.75ML, which has an ultimate completion date of September 25, 2024. Dakota Drug, Inc. holds a larger Indefinite Delivery Contract (IDC) with the DLA, valued at $999,999,999.00, under the DLA Troop Support Medical's...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Dakota Drug, Inc., a self-certified small disadvantaged business, for the supply of the pharmaceutical product WEGOVY 2.4 MG/0.75 ML PEN 0.75ML. The contract has a ceiling value of $2,545.02 and a period of performance ending on March 12, 2024. This award was made without the use of a set-aside. Dakota Drug, Inc. has over two decades of experience as a prime contractor to the...
  • SPE2DB24D8001
    Indefinite Delivery Contract
  • SPE2DB24D8001-SPE2DB25FKYTN
    Delivery Order

The U.S. Defense Logistics Agency (DLA) awarded a delivery order contract worth $1,286.46 to Dakota Drug, Inc., a self-certified small disadvantaged business, for the supply of WEGOVY 2.4 MG/0.75 ML PEN 0.75ML pharmaceutical products. This contract, identified as SPE2DB24D8001, is part of the DLA Troop Support Medical's ECAT Generation V Program, which enables Dakota Drug, Inc. to provide a broad range of pharmaceutical and medical supplies to support U.S. Armed Forces medical operations. The contract has a performance period extending through October 25, 2024, and is a firm fixed-price delivery order with no set-aside designation.

Generated 1/23/25, 9:32 AM